Published in Cancer Res on June 15, 2008
Matrix metalloproteinases: regulators of the tumor microenvironment. Cell (2010) 12.90
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia (2010) 2.07
Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models. Int J Cancer (2011) 2.01
Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules. Proc Natl Acad Sci U S A (2013) 1.23
Epithelial-mesenchymal transition: general principles and pathological relevance with special emphasis on the role of matrix metalloproteinases. Cold Spring Harb Perspect Biol (2012) 1.20
The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia (2009) 1.20
Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges. J Oncol (2009) 1.12
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice. Br J Cancer (2012) 1.10
Dental enamel development: proteinases and their enamel matrix substrates. ISRN Dent (2013) 1.10
Identification of ovarian cancer metastatic miRNAs. PLoS One (2013) 1.09
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Targeting the EGF receptor for ovarian cancer therapy. J Oncol (2009) 0.96
Modulation of cell-cell junctional complexes by matrix metalloproteinases. J Dent Res (2012) 0.95
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma. Clin Cancer Res (2012) 0.94
Expression profiling of primary and metastatic ovarian tumors reveals differences indicative of aggressive disease. PLoS One (2014) 0.92
Cancer cells induced to express mesenchymal phenotype release exosome-like extracellular vesicles carrying tissue factor. J Biol Chem (2012) 0.91
MUC1 regulates expression of multiple microRNAs involved in pancreatic tumor progression, including the miR-200c/141 cluster. PLoS One (2013) 0.90
MMP20 cleaves E-cadherin and influences ameloblast development. Cells Tissues Organs (2011) 0.90
Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen. Mol Cancer Res (2009) 0.89
Temporal changes in MMP mRNA expression in the lens epithelium during anterior subcapsular cataract formation. Exp Eye Res (2008) 0.89
TIEG1 inhibits breast cancer invasion and metastasis by inhibition of epidermal growth factor receptor (EGFR) transcription and the EGFR signaling pathway. Mol Cell Biol (2011) 0.88
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma. Future Oncol (2009) 0.88
Matrix metalloproteinase-9 in homocysteine-induced intestinal microvascular endothelial paracellular and transcellular permeability. J Cell Biochem (2012) 0.87
Serial analysis of gene expression of lobular carcinoma in situ identifies down regulation of claudin 4 and overexpression of matrix metalloproteinase 9. Breast Cancer Res (2008) 0.87
Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells. Epigenetics (2012) 0.87
Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer (2011) 0.86
Protein arginine methyltransferase 7 promotes breast cancer cell invasion through the induction of MMP9 expression. Oncotarget (2015) 0.86
Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers. Virchows Arch (2012) 0.85
EGFR may couple moderate alcohol consumption to increased breast cancer risk. Breast Cancer (Dove Med Press) (2009) 0.85
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res (2016) 0.85
Activated epidermal growth factor receptor in ovarian cancer. Cancer Treat Res (2009) 0.84
Interaction of Snail and p38 mitogen-activated protein kinase results in shorter overall survival of ovarian cancer patients. Virchows Arch (2010) 0.84
MMP20 modulates cadherin expression in ameloblasts as enamel develops. J Dent Res (2013) 0.84
Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results. Isr J Chem (2012) 0.83
The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration. J Biol Chem (2012) 0.83
Overexpression of CD157 contributes to epithelial ovarian cancer progression by promoting mesenchymal differentiation. PLoS One (2012) 0.82
Lysophosphatidic Acid disrupts junctional integrity and epithelial cohesion in ovarian cancer cells. J Oncol (2012) 0.82
Netrin-1 induces MMP-12-dependent E-cadherin degradation via the distinct activation of PKCα and FAK/Fyn in promoting mesenchymal stem cell motility. Stem Cells Dev (2014) 0.81
Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src. J Invest Dermatol (2011) 0.80
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
Metastasis of ovarian cancer is mediated by kallikrein related peptidases. Clin Exp Metastasis (2013) 0.78
Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed) (2015) 0.76
Differential downregulation of e-cadherin and desmoglein by epidermal growth factor. Dermatol Res Pract (2012) 0.76
Means to the ends: The role of telomeres and telomere processing machinery in metastasis. Biochim Biophys Acta (2016) 0.75
Transcriptional factor snail controls tumor neovascularization, growth and metastasis in mouse model of human ovarian carcinoma. Clin Transl Med (2014) 0.75
Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal (2016) 0.75
Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma. Cancer Microenviron (2011) 0.75
M2 macrophages induce ovarian cancer cell proliferation via a heparin binding epidermal growth factor/matrix metalloproteinase 9 intercellular feedback loop. Oncotarget (2016) 0.75
Genetic variants in matrix metalloproteinase genes as disposition factors for ovarian cancer risk, survival, and clinical outcome. Mol Carcinog (2013) 0.75
Murine matrix metalloproteinase-20 overexpression stimulates cell invasion into the enamel layer via enhanced Wnt signaling. Sci Rep (2016) 0.75
Therapeutic Potential of Matrix Metalloproteinase Inhibition in Breast Cancer. J Cell Biochem (2017) 0.75
Cancer statistics, 2006. CA Cancer J Clin (2006) 30.71
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell (2002) 5.61
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol (2003) 5.22
Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells. J Cell Biol (1997) 4.22
Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol (2004) 3.64
ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation. Proc Natl Acad Sci U S A (2005) 3.57
Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci (2001) 3.51
ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol (2004) 3.18
The ins and outs of E-cadherin trafficking. Trends Cell Biol (2004) 2.70
Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys (2004) 2.41
The EGF receptor: a nexus for trafficking and signaling. Bioessays (2000) 2.02
Disassembling adherens junctions: breaking up is hard to do. Trends Cell Biol (2005) 2.00
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model. J Cell Biol (2005) 1.81
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
The biology of ovarian cancer. Semin Oncol (1998) 1.46
Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res (2005) 1.42
Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy. Cancer Res (2004) 1.41
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis (1999) 1.40
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res (2001) 1.32
EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res (2002) 1.31
Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res (2005) 1.31
Significance of epidermal growth factor receptor in advanced ovarian cancer. J Clin Oncol (1992) 1.31
Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer (1994) 1.27
Ligand-independent oncogenic signaling by the epidermal growth factor receptor: v-ErbB as a paradigm. Exp Cell Res (2003) 1.19
HER1/EGFR targeting: refining the strategy. Oncologist (2004) 1.18
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma. Mol Cell Endocrinol (2002) 1.16
Targeting the epidermal growth factor receptor. Br J Cancer (2004) 1.14
Matrix metalloproteinase inhibitors suppress transforming growth factor-beta-induced subcapsular cataract formation. Am J Pathol (2006) 1.14
PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res (2007) 1.13
Ischemia-induced cleavage of cadherins in NRK cells requires MT1-MMP (MMP-14). Am J Physiol Renal Physiol (2005) 1.13
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res (2002) 1.10
Oncogenic pathways implicated in ovarian epithelial cancer. Hematol Oncol Clin North Am (2003) 1.09
Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res (2005) 1.09
Production of extracellular matrix-degrading proteinases by primary cultures of human epithelial ovarian carcinoma cells. Cancer (1997) 1.06
Association of extracellular cleavage of E-cadherin mediated by MMP-7 with HGF-induced in vitro invasion in human stomach cancer cells. Eur Surg Res (2007) 1.05
Proteinase requirements of epidermal growth factor-induced ovarian cancer cell invasion. Int J Cancer (1998) 1.00
Anti-sense suppression of epidermal growth factor receptor expression alters cellular proliferation, cell-adhesion and tumorigenicity in ovarian cancer cells. Int J Cancer (2000) 0.98
Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog (2006) 0.98
Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer. Br J Cancer (2005) 0.97
Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol (2000) 0.94
Normal ovarian surface epithelium. Cancer Treat Res (2002) 0.93
Higher levels of soluble E-cadherin in cyst fluid from malignant ovarian tumours than in benign cysts. Anticancer Res (2001) 0.88
Coexpression of the HER-2 gene product, p185HER-2, and epidermal growth factor receptor, p170EGF-R, on epithelial ovarian cancers and normal tissues. Hybridoma (1998) 0.85
Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res (2005) 0.84
Preoperative serum E-cadherin assay in patients with ovarian carcinoma. Anticancer Res (1999) 0.84
Plasminogen activator/plasmin system suppresses cell-cell adhesion of oral squamous cell carcinoma cells via proteolysis of E-cadherin. Int J Oncol (2005) 0.82
Expression of matrix metalloproteinases-2 and -9 by cells isolated from the peritoneal fluid of women with ovarian carcinoma. Acta Cytol (2002) 0.80
Soluble adhesion molecules in serum and cyst fluid from patients with cystic tumours of the ovary. Hum Reprod (1998) 0.79
Use of proteomic patterns in serum to identify ovarian cancer. Lancet (2002) 16.38
Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat Cell Biol (2007) 6.15
Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res (2002) 3.64
Developmental transcription factor slug is required for effective re-epithelialization by adult keratinocytes. J Cell Physiol (2005) 2.91
Importance of communication between producers and consumers of publicly available experimental data. J Natl Cancer Inst (2005) 2.63
Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol (2012) 2.29
Membrane protease proteomics: Isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates. Proc Natl Acad Sci U S A (2004) 1.91
Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells. Cancer Res (2007) 1.90
Benign metastasizing leiomyoma: clonality, telomere length and clinicopathologic analysis. Mod Pathol (2006) 1.87
Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res (2004) 1.69
Mapping molecular networks using proteomics: a vision for patient-tailored combination therapy. J Clin Oncol (2005) 1.69
Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis (2008) 1.65
Proteases, extracellular matrix, and cancer: a workshop of the path B study section. Am J Pathol (2004) 1.52
Membrane type 1-matrix metalloproteinase: substrate diversity in pericellular proteolysis. Semin Cell Dev Biol (2007) 1.50
Arsenite interacts selectively with zinc finger proteins containing C3H1 or C4 motifs. J Biol Chem (2011) 1.45
Inhibition of poly(ADP-ribose) polymerase-1 by arsenite interferes with repair of oxidative DNA damage. J Biol Chem (2008) 1.44
Soluble epidermal growth factor receptor (sEGFR/sErbB1) as a potential risk, screening, and diagnostic serum biomarker of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2003) 1.43
Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res (2009) 1.43
Telomerase prolongs the lifespan of normal human ovarian surface epithelial cells without inducing neoplastic phenotype. J Soc Gynecol Investig (2004) 1.42
Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics (2003) 1.40
Cyclooxygenase-2 functions as a downstream mediator of lysophosphatidic acid to promote aggressive behavior in ovarian carcinoma cells. Cancer Res (2005) 1.39
Benzo(a)pyrene quinones increase cell proliferation, generate reactive oxygen species, and transactivate the epidermal growth factor receptor in breast epithelial cells. Cancer Res (2003) 1.39
Arsenite causes DNA damage in keratinocytes via generation of hydroxyl radicals. Chem Res Toxicol (2004) 1.37
Epidermal growth factor receptor inhibition promotes desmosome assembly and strengthens intercellular adhesion in squamous cell carcinoma cells. J Biol Chem (2004) 1.37
Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res (2011) 1.30
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer (2005) 1.29
PRL modulates cell cycle regulators in mammary tumor epithelial cells. Mol Endocrinol (2002) 1.26
Biomarker amplification by serum carrier protein binding. Dis Markers (2004) 1.26
Survival of metastatic gastric cancer: Significance of age, sex and race/ethnicity. J Gastrointest Oncol (2011) 1.25
Oxidative stress and apoptosis in metal ion-induced carcinogenesis. Free Radic Biol Med (2004) 1.25
Clinical proteomics and biomarker discovery. Ann N Y Acad Sci (2004) 1.24
Microenvironmental regulation of membrane type 1 matrix metalloproteinase activity in ovarian carcinoma cells via collagen-induced EGR1 expression. J Biol Chem (2006) 1.24
Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem (2013) 1.24
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer. Cancer Treat Res (2002) 1.22
Selective hydrolysis of triple-helical substrates by matrix metalloproteinase-2 and -9. J Biol Chem (2003) 1.22
Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res (2011) 1.21
The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia (2009) 1.20
Inorganic arsenic compounds cause oxidative damage to DNA and protein by inducing ROS and RNS generation in human keratinocytes. Mol Cell Biochem (2005) 1.19
Evaluation of primary HPV-DNA testing in relation to visual inspection methods for cervical cancer screening in rural China: an epidemiologic and cost-effectiveness modelling study. BMC Cancer (2011) 1.16
Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J Biol Chem (2003) 1.14
PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells. Mol Cancer Res (2007) 1.13
Poly(ADP-ribose) contributes to an association between poly(ADP-ribose) polymerase-1 and xeroderma pigmentosum complementation group A in nucleotide excision repair. J Biol Chem (2012) 1.13
Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med (2008) 1.12
Low concentration of arsenite exacerbates UVR-induced DNA strand breaks by inhibiting PARP-1 activity. Toxicol Appl Pharmacol (2008) 1.11
Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res (2002) 1.10
Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res (2009) 1.10
Down-regulation of integrin alpha2 surface expression by mutant epidermal growth factor receptor (EGFRvIII) induces aberrant cell spreading and focal adhesion formation. Cancer Res (2005) 1.09
Torg syndrome is caused by inactivating mutations in MMP2 and is allelic to NAO and Winchester syndrome. J Bone Miner Res (2007) 1.09
Modulation of the membrane type 1 matrix metalloproteinase cytoplasmic tail enhances tumor cell invasion and proliferation in three-dimensional collagen matrices. J Biol Chem (2009) 1.08
Calcium regulation of matrix metalloproteinase-mediated migration in oral squamous cell carcinoma cells. J Biol Chem (2002) 1.07
Polypyrimidine tract-binding protein (PTB) differentially affects malignancy in a cell line-dependent manner. J Biol Chem (2008) 1.07
Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR Am J Roentgenol (2010) 1.06
The skinny on Slug. Mol Carcinog (2010) 1.06
Integrin regulation of beta-catenin signaling in ovarian carcinoma. J Biol Chem (2011) 1.06
Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochem J (2011) 1.05
Enhanced ROS production and redox signaling with combined arsenite and UVA exposure: contribution of NADPH oxidase. Free Radic Biol Med (2009) 1.05
Functional relevance of urinary-type plasminogen activator receptor-alpha3beta1 integrin association in proteinase regulatory pathways. J Biol Chem (2006) 1.04
Localization of the activin signal transduction components in normal human ovarian follicles: implications for autocrine and paracrine signaling in the ovary. J Clin Endocrinol Metab (2002) 1.03
Proteinase suppression by E-cadherin-mediated cell-cell attachment in premalignant oral keratinocytes. J Biol Chem (2002) 1.02
Dual actions involved in arsenite-induced oxidative DNA damage. Chem Res Toxicol (2008) 1.02
Lysophosphatidic acid enhances epithelial ovarian carcinoma invasion through the increased expression of interleukin-8. Gynecol Oncol (2004) 1.02
Low-dose synergistic immunosuppression of T-dependent antibody responses by polycyclic aromatic hydrocarbons and arsenic in C57BL/6J murine spleen cells. Toxicol Appl Pharmacol (2010) 1.02
Slug/Snai2 is a downstream mediator of epidermal growth factor receptor-stimulated reepithelialization. J Invest Dermatol (2008) 1.02
Matrilysin over-expression in MCF-7 cells enhances cellular invasiveness and pro-gelatinase activation. Cancer Lett (2005) 1.01
Motility-related actinin alpha-4 is associated with advanced and metastatic ovarian carcinoma. Lab Invest (2008) 1.01
LPA-induced epithelial ovarian cancer (EOC) in vitro invasion and migration are mediated by VEGF receptor-2 (VEGF-R2). Gynecol Oncol (2005) 1.01
Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen. Cancer Lett (2005) 1.01
Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.01
Early detection of ovarian cancer with conventional and contrast-enhanced transvaginal sonography: recent advances and potential improvements. J Oncol (2012) 1.00
Activated epidermal growth factor receptor induces integrin alpha2 internalization via caveolae/raft-dependent endocytic pathway. J Biol Chem (2006) 1.00
Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res (2011) 1.00
Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res (2010) 1.00
As(III) inhibits ultraviolet radiation-induced cyclobutane pyrimidine dimer repair via generation of nitric oxide in human keratinocytes. Free Radic Biol Med (2008) 0.99
Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat Res (2009) 0.99
Contributions of reactive oxygen species and mitogen-activated protein kinase signaling in arsenite-stimulated hemeoxygenase-1 production. Toxicol Appl Pharmacol (2006) 0.99
Lysophosphatidic acid down-regulates stress fibers and up-regulates pro-matrix metalloproteinase-2 activation in ovarian cancer cells. Mol Cancer Res (2007) 0.99
Bisphosphonate effects on the behaviour of oral epithelial cells and oral fibroblasts. Arch Oral Biol (2010) 0.99
Mesenchymal transformation in epithelial ovarian tumor cells expressing epidermal growth factor receptor variant III. Mol Carcinog (2006) 0.98
Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics (2008) 0.98
Reduction of arsenite-enhanced ultraviolet radiation-induced DNA damage by supplemental zinc. Toxicol Appl Pharmacol (2013) 0.97
Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res (2010) 0.97
Thymidylate synthase gene variations: predictive and prognostic markers. Mol Cancer Ther (2009) 0.97
Microenvironmental regulation of chemokine (C-X-C-motif) receptor 4 in ovarian carcinoma. Mol Cancer Res (2010) 0.97
Poly(ADP-ribose) polymerase-1 inhibition by arsenite promotes the survival of cells with unrepaired DNA lesions induced by UV exposure. Toxicol Sci (2012) 0.97